证券代码：301507 证券简称：民生健康 公告编号：2024-018 杭州民生健康药业股份有限公司 关于续聘 2024 年度会计师事务所的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 中汇会计师事务所（特殊普通合伙）（以下简称"中汇会计师事务所"）具有 证券、期货相关业务执业资格以及丰富的审计工作经验与能力。该所在担任公司 2023 年度审计机构期间，遵循了《中国注册会计师独立审计准则》等相关法律、 法规和政策的要求，勤勉尽责、细致严谨，并坚持独立、客观、公正的审计准则， 按时完成年度财务审计业务，为公司出具了标准无保留意见的审计报告，客观、 公正地反映了公司的财务状况和经营成果。 为保持公司审计工作的连续性和稳定性，并经公司审计委员会审议确认，公 司董事会拟续聘中汇会计师事务所（特殊普通合伙）为公司 2024 年度审计机构， 聘期一年，并提请股东大会授权公司经营管理层合理确定审计费用并签署相关文 件。 二、拟聘任会计师事务所基本信息 （一）机构信息 1、基本信息 中汇会计师事务所，于 2013 年 12 月转制为特殊普通合伙，管理总部设立于 ...

经核查独立董事丁建萍先生、刘玉龙先生、朱狄敏先生的任职经历及签署的 相关自查文件等内容，公司董事会认为上述人员未在公司担任独立董事以外的任 何职务，也未在公司主要股东担任任何职务，与公司以及主要股东之间不存在利 害关系或其他可能妨碍其进行独立客观判断的关系，不存在其他影响独立董事独 立性的情况，因此，公司独立董事符合《上市公司独立董事管理办法》《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关法 律法规及《公司章程》中关于独立董事独立性的相关要求。 杭州民生健康药业股份有限公司 董事会对独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 及《公司章程》等相关规定，结合独立董事出具的《独立董事关于 2023 年度独 立性的自查报告》，董事会对公司在任独立董事丁建萍先生、刘玉龙先生、朱狄 敏先生的独立性情况进行了评估。 杭州民生健康药业股份有限公司董事会 2024 年 4 月 24 日 ...

本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 杭州民生健康药业股份有限公司（以下简称"公司"）于2024年4月22日召 开第一届董事会第十六次会议及第一届监事会第十二次会议，分别审议通过了 《关于公司及全资子公司使用自有资金进行现金管理的议案》，同意公司及全资 子公司在最高额不超过人民币6.5亿元的额度内进行现金管理，有效期自股东大 会审议通过之日起12个月。在上述额度及有效期内，资金可循环滚动使用，期限 内任一时点的金额不应超过前述授权额度。该议案尚需提交股东大会审议。现将 具体情况公告如下： 一、现金管理概况 （一）现金管理目的 在不影响日常经营资金需求并有效保障资金安全的前提下，公司及全资子公 司使用闲置自有资金适度开展现金管理，有利于提高公司资金利用率，增加公司 收益，最大化利用闲置资金。 （二）现金管理额度及期限 证券代码：301507 证券简称：民生健康 公告编号：2024-023 杭州民生健康药业股份有限公司 关于公司及全资子公司使用自有资金进行现金 管理的公告 公司及全资子公司拟在最高额不超过人民币 6.5 亿元的额度内，使用闲置自 有 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 234,624,438.88, representing a 5.78% increase compared to CNY 221,797,622.60 in the same period last year[5]. - Net profit attributable to shareholders was CNY 58,872,271.43, up 6.51% from CNY 55,273,336.61 year-on-year[5]. - The total operating revenue for Q1 2024 was CNY 234,624,438.88, an increase of 5.9% compared to CNY 221,797,622.60 in Q1 2023[25]. - The net profit for Q1 2024 reached CNY 58,872,271.43, representing a 9.4% increase from CNY 55,273,336.61 in Q1 2023[26]. - The total operating costs for Q1 2024 were CNY 170,660,081.11, up from CNY 157,112,950.31 in the same period last year, reflecting a year-over-year increase of 8.8%[25]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 20.80% to CNY 134,109,804.54, compared to CNY 111,020,049.15 in the previous year[5]. - Total cash inflow from operating activities reached CNY 301,545,548.82, up from CNY 271,803,192.39, reflecting a growth of 10.9%[30]. - Cash outflow from operating activities was CNY 167,435,744.28, compared to CNY 160,783,143.24, indicating a rise of 4.1%[30]. - The net cash flow from investing activities was -CNY 49,693,920.20, an improvement from -CNY 98,976,811.16 in the previous period[30]. - The ending cash and cash equivalents balance increased to CNY 512,227,863.05 from CNY 51,925,842.84, marking a significant rise[31]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 1,737,209,174.50, a 5.43% increase from CNY 1,647,809,834.45 at the end of the previous year[5]. - The total liabilities increased to CNY 205,276,691.49 in Q1 2024 from CNY 174,749,622.87 in Q1 2023, marking a rise of 17.4%[23]. - The total current assets as of March 31, 2024, amounted to CNY 1,171,882,824.56, an increase from CNY 1,160,704,900.90 at the beginning of the period, reflecting a growth of approximately 0.15%[21]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,939[15]. - The company reported a total of 238,000,000 shares under lock-up prior to the IPO, with a release date set for 2026[19]. - The number of shares held by the top ten unrestricted shareholders includes 904,783 shares held by Gao Canxuan and 770,798 shares held by Lu Xiaoxu[18]. - The company has a total of 4,593,003 shares under lock-up from offline placements, with a release date in March 2024[19]. Inventory and Receivables Management - Accounts receivable decreased by 40.20% to CNY 20,457,486.94, attributed to improved management of receivables[10]. - Inventory decreased by 33.70% to CNY 69,823,974.78, due to effective inventory management during the reporting period[10]. - Inventory decreased significantly from CNY 105,315,599.46 to CNY 69,823,974.78, indicating a reduction of approximately 33.7%[21]. - Accounts receivable decreased from CNY 34,207,790.42 to CNY 20,457,486.94, a decline of about 40.2%[21]. Government Subsidies and Other Income - The company received government subsidies amounting to CNY 1,340,821.47, contributing to other income growth of 63.03%[12]. - The company received CNY 5,534,842.83 in other cash related to operating activities, compared to CNY 2,021,722.59 previously, showing a growth of 173.5%[30]. Earnings and Expenses - The company's basic earnings per share decreased by 19.05% to CNY 0.1700, down from CNY 0.2100 in the same period last year[5]. - The research and development expenses for Q1 2024 were CNY 10,242,656.68, slightly decreased from CNY 10,326,983.01 in the previous year[26]. - The company paid CNY 30,202,401.32 in taxes, up from CNY 25,398,009.39, reflecting an 18.4% increase[30]. Financial Management - The company is actively managing its financial assets, with a focus on optimizing liquidity and reducing inventory levels[20]. - The company has shown a significant increase in other non-current assets, which rose to CNY 292,298,503.11 from CNY 213,799,229.97 year-over-year, reflecting a growth of 36.7%[23]. - The company is focusing on expanding its market presence and developing new products, although specific details on new products or technologies were not provided in the content[28]. Audit Status - The company has not undergone an audit for the Q1 2024 report[32].

目 录 页 次 一、年度募集资金存放与使用情况鉴证报告 1-2 二、杭州民生健康药业股份有限公司 2023 年度募集资金 存放与使用情况的专项报告 3-10 年度募集资金存放与使用情况鉴证报告 中汇会鉴[2024]3661号 杭州民生健康药业股份有限公司全体股东： 我们鉴证了后附的杭州民生健康药业股份有限公司(以下简称民生健康公司) 管理层编制的《2023年度募集资金存放与使用情况的专项报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供民生健康公司年度报告披露时使用，不得用作任何其他目的。 我们同意将本鉴证报告作为民生健康公司年度报告的必备文件，随同其他文件一起 报送并对外披露。 二、管理层的责任 民生健康公司管理层的责任是提供真实、合法、完整的相关资料，按照《深圳 证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作(2023年12 月修订)》及相关格式指引编制《2023年度募集资金存放与使用情况的专项报告》， 并保证其内容真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 三、注册会计师的责任 我们的责任是在实施鉴证工作的基础上对民生健康公司管理层编制的《2023 年度募集资金存放 ...

Financial Performance - The company's operating revenue for 2023 reached ¥581,733,150.83, representing a 6.33% increase compared to ¥547,120,543.92 in 2022[18]. - The net profit attributable to shareholders for 2023 was ¥85,633,797.95, an increase of 8.38% from ¥78,982,772.38 in the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥79,186,962.41, reflecting a 12.61% increase from ¥70,290,378.16 in 2022[18]. - The net cash flow from operating activities for 2023 was ¥108,152,661.81, up 13.47% from ¥95,314,128.98 in the previous year[18]. - Basic earnings per share for 2023 were ¥0.29, a decrease of 3.33% compared to ¥0.30 in 2022[18]. - Total assets increased by 115.32% year-on-year to CNY 1,647,809,834.45 at the end of 2023[19]. - Net assets attributable to shareholders increased by 147.94% year-on-year to CNY 1,473,060,211.58 at the end of 2023[19]. - The company reported a net profit of CNY 55,273,336.61 in Q1 2023, with a decrease in net profit to CNY 3,961,507.18 in Q4 2023[21]. - The company generated operating cash flow of CNY 111,020,049.15 in Q1 2023, but reported a negative cash flow of CNY -31,653,836.36 in Q2 2023[21]. - The company achieved a revenue of CNY 582 million in 2023, representing a year-on-year growth of 6.33%[52]. - Net profit attributable to shareholders reached CNY 86 million, an increase of 8.38% compared to the previous year[52]. - Revenue from vitamin and mineral supplement series was CNY 570 million, up 7.39% year-on-year, with multi-element tablets generating CNY 476 million, a growth of 8.47%[52]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of ¥1.00 per 10 shares to all shareholders based on the total share capital as of December 31, 2023[4]. - The total distributable profit for the period was CNY 145,064,617.14, indicating a strong profit generation capability[178]. - The total cash dividend amount for the reporting period was CNY 35,655,433, which represents 100% of the total profit distribution[178]. - The company’s profit distribution plan includes a cash dividend of CNY 1.00 per 10 shares, with no stock dividends or capital increases planned[178]. Market and Product Development - The company is focusing on expanding its market presence and enhancing its product offerings through new product development and technology[4]. - The dietary supplement market in China is expected to continue stable growth, driven by increasing health awareness and consumption demand[31]. - The company’s main product, 21 Jinweita® Multivitamin Tablets, is positioned in the OTC market, which is experiencing strong growth due to rising self-medication trends[30]. - The company plans to enhance its product development capabilities in response to new regulations and market demands for health products[33]. - The company is focusing on the research, production, and sales of vitamin and mineral supplements, enhancing its product matrix and brand influence[36]. - The company launched new sub-brands under "21 Jinweita," including "21 Jinweita Bei+" for adult nutrition and "Little Jinweita" for children's nutrition, expanding its product matrix[59]. - The company completed the development of several new products, including vitamin D formulations and multi-nutrient supplements, with approvals obtained for commercialization[72]. - The company is focusing on expanding its product pipeline, including functional probiotics and health supplements tailored for specific populations[72]. Research and Development - The company invested CNY 29.56 million in R&D, accounting for 5.08% of total revenue, and added 3 new invention patents[53]. - The number of R&D personnel remained stable at 61, with a slight increase in the proportion of master's degree holders to 16.39%[73]. - Research and development investments have increased by 30% in 2023, focusing on advanced pharmaceutical technologies[153]. - The company is investing heavily in R&D, with a budget allocation of 150 million RMB for new technologies and product development[143]. Risk Management - The company faces risks including product structure singularity, distributor management, and changes in industry policies[4]. - The company emphasizes the importance of risk awareness among investors regarding its future plans and market conditions[4]. - The company has faced uncertainty regarding its ability to continue as a going concern, as indicated by recent audit reports[20]. - The company will closely monitor industry policy changes, which are expected to remain stringent, and will adapt its operations accordingly to mitigate regulatory risks[111]. - The company is focused on diversifying its product matrix and deepening its channel system to address the risks associated with a narrow product range[109]. - The company has established a stable and trustworthy relationship with its main distributors, which helps to mitigate distributor management risks[110]. Corporate Governance - The company maintains complete independence in assets, personnel, finance, institutions, and business from its controlling shareholders and actual controllers[129]. - The company has established an independent financial department with a standardized financial accounting system, ensuring no interference from controlling shareholders in financial decisions[132]. - The company has a robust corporate governance structure, complying with relevant laws and regulations without significant discrepancies[127]. - The company emphasizes investor relations management, ensuring fair and effective communication with investors through various channels[124]. - The company has established a performance evaluation and incentive mechanism in place for senior management, aligning with its development needs[125]. - The company has not reported any significant asset or equity sales during the reporting period[98][99]. - The company has not faced any objections from independent directors regarding board resolutions during the reporting period[123]. Environmental Compliance - The company is classified as a key pollutant discharge unit and complies with various environmental protection laws and standards[190]. - The company has obtained all necessary environmental protection administrative permits, which are currently valid[191]. - The company's pollution discharge permit is valid from July 27, 2023, to July 26, 2028[192]. - The company has completed environmental impact assessments for all operational projects and has received the necessary approvals[191]. - The company ensures effective collection and treatment of pollutants generated during production activities, achieving compliance with discharge standards[199]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[143]. - New product launches are expected to contribute an additional 200 million RMB in revenue over the next year[143]. - The company is considering strategic acquisitions to enhance its product portfolio, with a target of identifying at least two potential candidates by the end of Q2 2024[143]. - The company plans to continue its financial management strategy using its own funds[137]. - The company aims to enhance its core competitiveness in the vitamin and mineral supplement sector, aligning with national health strategies[101].

2023年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：杭州民生健康药业股份有限公司 金额单位：人民币万元 | 非经营性资金 | | 占用方与上市公 | 上市公司核算的 | 2023 | 年期初占用 | 年度占用累 2023 | | 年度占 2023 | 年度 2023 | 2023 | 年期末 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 占用 | 资金占用方名称 | 司的关联关系 | 会计科目 | | 资金余额 | 计发生金额(不 | | 用资金的利 | 偿还累计 | | 占用资金余 | 占用形成原因 | 占用性质 | | | | | | | | 含利息) | | 息(如有) | 发生金额 | | 额 | | | | 控股股东、实际 | - | - | - | | - | | - | - | | - | - | - | 非经营性 | | 控制人及其附 | - | - | - | | - | | - | - | | - | - | - | 非经营性 | | ...

作为杭州民生健康药业股份有限公司（以下简称"公司"）第一届董事会独 立董事，2023年度本人严格按照《公司法》《证券法》《上市公司治理准则》《上 市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第2号——创业板上市公司规范运作》等法律法规 及《公司章程》《独立董事工作细则》等有关规定，忠实、勤勉履行职责，充分 发挥独立董事的作用，谨慎、认真行使法律所赋予的权利，有效监督公司运作 的合理性及公平性，切实维护公司的整体利益和全体股东尤其是中小股东的合 法权益。现将本人2023年度的履职情况报告如下： 一、独立董事的基本情况 朱狄敏，1982 年 1 月出生，中国国籍，无境外永久居留权，博士研究生学 历。2007 年 9 至 2008 年 6 月任浙江大学公法与比较法研究助理研究员；2008 年 6 月至 2010 年 2 月任杭州拱墅区人民法院法官助理；2010 年 2 月至 2014 年 12 月任杭州市发展研究中心（杭州市委政策研究室）主任科员；2014 年 12 月至今 任浙江工商大学教师。现任浙江工商大学法学院硕士生导师、教授职称，兼任本 公司、上海贺鸿电 ...

财通证券股份有限公司 关于杭州民生健康药业股份有限公司 使用银行承兑汇票支付募投项目资金并以募集资金等额置 换的核查意见 财通证券股份有限公司（以下简称"保荐机构"）作为杭州民生健康药业股 份有限公司（以下简称"民生健康"或"公司"）首次公开发行股票并在创业板 上市的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》《上市公司监管指引第 2 号——上市公司募集资金管理和使 用的监管要求》等有关规定，对公司拟使用银行承兑汇票支付募投项目资金并以 募集资金等额置换的事项进行了审慎核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意杭州民 生健康药业股份有限公司首次公开发行股票注册的批复》（证监许可〔2023〕1204 号）同意注册，并根据深圳证券交易所《关于杭州民生健康药业股份有限公司人 民币普通股股票在创业板上市的通知》（深证上〔2023〕821 号），公司向社会 公开发行人民币普通股（A 股）8,913.8600 万股，发行价格为 10.00 元/股 ...

证券代码：301507 证券简称：民生健康 公告编号：2024-017 杭州民生健康药业股份有限公司 2023 年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何虚 假记载、误导性陈述或者重大遗漏。 根据中国证券监督管理委员会发布的《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求》和深圳证券交易所发布的《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关规定，杭州民生 健康药业股份有限公司（以下简称"公司"）就 2023 年度募集资金存放与使用情况 说明如下： 一、募集资金基本情况 (一) 实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意杭州民生健康药业股份有限公司首次公 开发行股票注册的批复》(证监许可[2023]1204号)同意注册，并根据深圳证券交易 所《关于杭州民生健康药业股份有限公司人民币普通股股票在创业板上市的通知》 （深证上〔2023〕821号），公司向社会公开发行了人民币普通股(A股)股票8,913.86 万股，发行价为每股人民币为10.00元，共计募集资金总额为人民币8 ...